Claim and evidence Close ×
Exscientia’s IPO prospectus (30 September 2021) states that it began a Phase 1 trial of EXS21546 in December 2020 and that it “originated the first three AI-designed precision drug candidates to enter human clinical trials”. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source; Context: primary · 1 source
Date 2021-09-30 · publication Records dated 2021 → Role Articulation Register (kind of text) Nonfiction Scope of the passage A prospectus statement by the issuer; the priority wording is the company’s and is quoted, not adopted. Scope and limits The record documents what this text states, in its register; it is not evidence that the proposition is true and implies no influence on or from any other text. The company’s own statement; no clinical-trial registry entry was retrieved. It rests on the same passages as the record of the company’s statement (recorded separately).
The evidence 02 primary source Supports the claim
Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares ↗ Exscientia plc (filed with the US SEC) · 2021-09-30
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “Among these is our most advanced internally developed drug candidate, EXS21546. We began the first Phase 1 clinical trial of this drug candidate in December 2020” Location in source Business, "Demonstrating the Impact of our AI"
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Exscientia plc (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 4b5b5bf7d5e80cc8f35a5daeaf2c39ac6a9c04508d08ca692aaccda878c03973). SEC EDGAR 424B4, accession 0001104659-21-122290; prospectus dated September 30, 2021; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Exscientia plc (filed with the US SEC), “Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares”, 2021-09-30. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (26 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Context only
Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares ↗ Exscientia plc (filed with the US SEC) · 2021-09-30
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “We originated the first three AI-designed precision drug candidates to enter human clinical trials.” Location in source Business, "Demonstrating the Impact of our AI"
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Exscientia plc (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 4b5b5bf7d5e80cc8f35a5daeaf2c39ac6a9c04508d08ca692aaccda878c03973). SEC EDGAR 424B4, accession 0001104659-21-122290; prospectus dated September 30, 2021; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Exscientia plc (filed with the US SEC), “Exscientia plc prospectus (Rule 424(b)(4)), initial public offering of American Depositary Shares”, 2021-09-30. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (14 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. The company's priority claim, quoted and attributed; not adopted. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. A passage of the document meets the proposition’s criterion. The record documents what the text states, in its register (fiction and satire are labelled); it is not evidence that the proposition is true and implies no influence on or from another text.
Date. Dated by the prospectus; the trial start month (December 2020) is the company's statement within it.
Record ID aib-arg-p3-exscientia-2021